november AG

EANS-News: november AG announces interim half-year financial results for 2009

november AG continues economic upturn/ Preliminary results confirm positive trend

@@start.t1@@--------------------------------------------------------------------------------   Corporate news transmitted by euro adhoc. The issuer/originator is solely   responsible for the content of this announcement. --------------------------------------------------------------------------------@@end@@

finances

Munic (euro adhoc) - The preliminary results of the 2nd quarter of fiscal year 2009 confirm the upward trend already reported for the 1st quarter. Despite the discontinuation of the AXIS-SHIELD business, with approx. EUR 3,6 mio, the preliminary sales revenues of the november AG are only slightly below last year´s figures. Considerably improved consolidated results of approx. EUR + 3,0 mio (half-year result 2008: rounded EUR +0,4 mio) are projected as well as a clearly improved consolidated shareholders´ equity of approx. EUR -2,7 mio (31.12.2008: rounded EUR -5,7 mio) and a liquidity improvement of EUR 1,1 mio (31.12.2008: round EUR 0,58 mio).  According to Dr. Dirk Zurek, CEO of november AG, this improved liquidity and the planned capital measures will put november AG in the position to finance further future acquisitions.

Starting August 14, 2009, the final half-year report as of June 30, 2009 with detailed financial numbers and information will be published on the website of the november AG under www.november.de/nc/unternehmen/berichte.html

If you want to keep up to date with all developments and activities of the november AG, please subscribe to the newsletter.

@@start.t2@@end of announcement                                                 euro adhoc
--------------------------------------------------------------------------------@@end@@

ots Originaltext: november AG
Im Internet recherchierbar: http://www.presseportal.ch

Further inquiry note:
Dr. Dirk Zurek
CEO
Tel.: +49 (0) 6221 8278-0
E-Mail: ir@november.de

Branche: Biotechnology
ISIN:      DE000A0S9N72
WKN:        A0S9N7
Index:    CDAX, Prime All Share, Technologie All Share
Börsen:  Frankfurt / regulated dealing/prime standard
              Berlin / free trade
              Stuttgart / free trade
              Düsseldorf / free trade
              Hannover / free trade
              München / free trade



Weitere Meldungen: november AG

Das könnte Sie auch interessieren: